BioCryst制药 BCRX 深 沪
等待开盘 07-22 09:30:00 美东时间
8.52
-0.090
-1.05%
华盛通- 最 高8.745
- 今 开8.63
- 成交量 332.02万股
- 最 低 8.495
- 昨 收 8.61
- 总市值 17.81亿
- 52周最高 11.31
- 市盈率 静 --
- 换手率 1.59%
- 52周最低 6.015
- 委 比 78.67%
- 总股本 2.09亿
- 历史最高 19.99
- 量 比 1.07
- 振 幅 2.90%
- 历史最低 1.08
- 每 手 1
- 风险率 1.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioCryst to Report Second Quarter 2025 Financial Results on August 4
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will report its second quarter 2025 financial results on August 4, 2025, and host a conference call at 8:30 a.m. ET that day. The call can be accessed via phone or webcast, with details provided. BioCryst is a global biotech company focused on rare diseases, including hereditary angioedema, and has developed ORLADEYO® (berotralstat). For more information, visit the company's website or Li...
07-21 11:00
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
BioCryst Pharmaceuticals, Inc. announced new research findings on the challenges of current HAE treatments for pediatric patients under 12 and their caregivers, to be presented at the 2025 US HAEA National Summit. CEO Jon Stonehouse emphasized the company's commitment to improving HAE patients' lives and highlighted BioCryst's role in developing ORLADEYO, the first oral, once-daily prophylactic therapy for adults and adolescents with HAE. Safety ...
07-09 11:00
BioCryst appoints Babar Ghias as CFO
BioCryst Pharmaceuticals (NASDAQ:BCRX) on Monday announced the appointment of Babar Ghias as chief financial officer and head of corporate development. Ghias joins BioCryst from AvenCell Therapeutics,...
07-07 19:38
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
BioCryst Pharmaceuticals appoints Babar Ghias as Chief Financial Officer and head of corporate development. Ghias, formerly CFO at AvenCell Therapeutics and Marathon Pharmaceuticals, brings extensive experience in deal-making and operational leadership, particularly in rare disease companies. He has raised over $1 billion in capital and successfully launched multiple biotechnology companies. Ghias is expected to support BioCryst’s growth and capi...
07-07 11:00
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
BioCryst Sells BioCryst Ireland to Neopharmed Gentili
The latest update is out from BioCryst ( ($BCRX) ). On June 27, 2025, BioCryst ...
06-30 23:55
BioCryst Sells European ORLADEYO Business for $264M
BioCryst ( ($BCRX) ) just unveiled an announcement. On June 27, 2025, BioCryst ...
06-27 19:28
BioCryst Pharmaceuticals Agrees To Sell Its European Orladeyo (Berotralstat) Business To Neopharmed Gentili For Up To $264M
Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones.BioCryst plans to use proceeds to retire all remaining term
06-27 19:04
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
BioCryst Pharmaceuticals has agreed to sell its European ORLADEYO business to Neopharmed Gentili for up to $264 million. The deal includes a $250 million upfront payment and up to $14 million in future milestones. BioCryst plans to use the proceeds to repay $249 million in debt, eliminating $70 million in future interest payments. The company expects to end 2027 with $700 million in cash and no term debt, a $400 million increase from prior guidan...
06-27 11:00
